Frontlight ResearchEarly access
SuspendedNo phase
Crossmodal Learning in Therapeutic Processes (Task 2-1)
Key facts
- Who runs it
- Universitätsklinikum Hamburg-Eppendorf
- Where
- Germany1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Suspended
- People taking part
- 44 people, planned
- Started
- 14 Apr 2021
- Ended
- Dec 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Vibro-tactile stimulation
- Placebo Control
- Record updated
- 23 May 2023
- Why it stopped
- Unability to include participants during Covid pandemic
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Ischemic stroke according to ICD 10 I61-I69
- Deficit still existing (Rankin score of at least 1 at inclusion)
- Age >= 18, <=80
- Existing declaration of consent
Who cannot take part
- Pregnancy
- Lacking capacity for consent
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Interventional study of the effects of vibro-tactile feedback on behavioral deficits and learning during motor training in patients with stroke.
The 2 groups in the trial
- StimulationTreatment being tested
During motor training participants in the stimulation arm receive vibro-tactile feedback applied to their fingers when touching an object as measured by force-sensing resistors mounted to the fingertips.
Treatment: Vibro-tactile stimulation
- ControlPlacebo, for comparison
The control group receives the same motor training with the same derives (force-sensing resistors, vibro-tactile stimulators) mounted to the hands but receives no stimulation.
Treatment: Placebo Control
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- SFB TRR 169/A3 (2.FP) Crossmodal Learning in Health and Neurological Disease: Neurocomputational Representation and Therapeutic Application (Task 2-1)
- Record updated
- 23 May 2023